Adjuvant Chemotherapy for High-Risk Localized Prostate Cancer: Time for Change or Need More Time to Change?

Affiliations

Comment

Jeanny B Aragon-Ching. J Clin Oncol. 2019.

. 2019 Sep 1;37(25):2296-2297.

doi: 10.1200/JCO.19.00977. Epub 2019 Jul 1.

No abstract available

Comment in

Reply to J.B. Aragon-Ching.
Rosenthal SA, Hu C, Sartor O, Feng FY, Sandler HM. Rosenthal SA, et al. J Clin Oncol. 2019 Sep 1;37(25):2297-2298. doi: 10.1200/JCO.19.01332. Epub 2019 Jul 1. J Clin Oncol. 2019. PMID: 31260645 No abstract available.

Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.
Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Horwitz EM, Raben A, Peters CA, Feng FY, Shipley WU, Sandler HM. Rosenthal SA, et al. J Clin Oncol. 2019 May 10;37(14):1159-1168. doi: 10.1200/JCO.18.02158. Epub 2019 Mar 12. J Clin Oncol. 2019. PMID: 30860948 Free PMC article. Clinical Trial.